StreetInsider.com News Articles

Medincell: Videoconference and Publication of Annual Financial Results, Tuesday, June 16, 2026

Thu, 28 May 2026 12:00:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:

Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange.

The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders.

Videoconference in English, 6:00pm CEST / 12:00pm ET
>https://www.medincell.com/annual-results-2025-2026-register/

Videoconference in French, 6:00pm CEST / 12:00pm

Medincell: Videoconference and Publication of Annual Financial Results, Tuesday, June 16, 2026

Thu, 28 May 2026 12:00:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange.
The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders.
Videoconference in English, 6:00pm CEST / 12:00pm ET
>https://www.medincell.com/annual-results-2025-2026-register/
Videoconference in French, 6:00pm CEST / 12:00pm

Medincell: Videoconference and Publication of Annual Financial Results, Tuesday, June 16, 2026

Thu, 28 May 2026 12:00:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange.
The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders.
Videoconference in English, 6:00pm CEST / 12:00pm ET
>https://www.medincell.com/annual-results-2025-2026-register/
Videoconference in French, 6:00pm CEST / 12:00pm

Medincell: Videoconference and Publication of Annual Financial Results, Tuesday, June 16, 2026

Thu, 28 May 2026 12:00:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange.
The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders.
Videoconference in English, 6:00pm CEST / 12:00pm ET
>https://www.medincell.com/annual-results-2025-2026-register/
Videoconference in French, 6:00pm CEST / 12:00pm

Medincell: Videoconference and Publication of Annual Financial Results, Tuesday, June 16, 2026

Thu, 28 May 2026 12:00:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange.
The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders.
Videoconference in English, 6:00pm CEST / 12:00pm ET
>https://www.medincell.com/annual-results-2025-2026-register/
Videoconference in French, 6:00pm CEST / 12:00pm

Medincell: Videoconference and Publication of Annual Financial Results, Tuesday, June 16, 2026

Thu, 28 May 2026 12:00:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange.
The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders.
Videoconference in English, 6:00pm CEST / 12:00pm ET
>https://www.medincell.com/annual-results-2025-2026-register/
Videoconference in French, 6:00pm CEST / 12:00pm

Medincell: Videoconference and Publication of Annual Financial Results, Tuesday, June 16, 2026

Thu, 28 May 2026 12:00:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange.
The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders.
Videoconference in English, 6:00pm CEST / 12:00pm ET
>https://www.medincell.com/annual-results-2025-2026-register/
Videoconference in French, 6:00pm CEST / 12:00pm

Medincell: Videoconference and Publication of Annual Financial Results, Tuesday, June 16, 2026

Thu, 28 May 2026 12:00:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange.
The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders.
Videoconference in English, 6:00pm CEST / 12:00pm ET
>https://www.medincell.com/annual-results-2025-2026-register/
Videoconference in French, 6:00pm CEST / 12:00pm

Medincell: Videoconference and Publication of Annual Financial Results, Tuesday, June 16, 2026

Thu, 28 May 2026 12:00:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange.
The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders.
Videoconference in English, 6:00pm CEST / 12:00pm ET
>https://www.medincell.com/annual-results-2025-2026-register/
Videoconference in French, 6:00pm CEST / 12:00pm

Medincell: Videoconference and Publication of Annual Financial Results, Tuesday, June 16, 2026

Thu, 28 May 2026 12:00:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange.
The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders.
Videoconference in English, 6:00pm CEST / 12:00pm ET
>https://www.medincell.com/annual-results-2025-2026-register/
Videoconference in French, 6:00pm CEST / 12:00pm

Medincell: Videoconference and Publication of Annual Financial Results, Tuesday, June 16, 2026

Thu, 28 May 2026 12:00:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange.
The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders.
Videoconference in English, 6:00pm CEST / 12:00pm ET
>https://www.medincell.com/annual-results-2025-2026-register/
Videoconference in French, 6:00pm CEST / 12:00pm

Medincell: Videoconference and Publication of Annual Financial Results, Tuesday, June 16, 2026

Thu, 28 May 2026 12:00:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange.
The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders.
Videoconference in English, 6:00pm CEST / 12:00pm ET
>https://www.medincell.com/annual-results-2025-2026-register/
Videoconference in French, 6:00pm CEST / 12:00pm

Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June

Tue, 26 May 2026 12:00:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced that Christophe Douat, Chief Executive Officer, and Grace Kim, Chief Strategy Officer, U.S. Finance, will participate in the following leading U.S. investor conferences:
Jefferies Annual NY Biotech Conference

Dates: June 2-4, 2026

Location: New-York

Presentation: 9:55 AM ET June 4, 2026

Live webcast and replay:
https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/Bz7fjGhGyU3meEzqRduiXr

Evercore Summer Symposium

Dates: June 22-24, 2026

Location: Newport, Rhode Island

To schedule a meeting, please contact the conference organizers or reach out directly to Medincell.
About Medincell
Medincell is a clinical- and commercial-stage biopharmaceutical

Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June

Tue, 26 May 2026 12:00:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced that Christophe Douat, Chief Executive Officer, and Grace Kim, Chief Strategy Officer, U.S. Finance, will participate in the following leading U.S. investor conferences:
Jefferies Annual NY Biotech Conference

Dates: June 2-4, 2026

Location: New-York

Presentation: 9:55 AM ET June 4, 2026

Live webcast and replay:
https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/Bz7fjGhGyU3meEzqRduiXr

Evercore Summer Symposium

Dates: June 22-24, 2026

Location: Newport, Rhode Island

To schedule a meeting, please contact the conference organizers or reach out directly to Medincell.
About Medincell
Medincell is a clinical- and commercial-stage biopharmaceutical

Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June

Tue, 26 May 2026 12:00:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced that Christophe Douat, Chief Executive Officer, and Grace Kim, Chief Strategy Officer, U.S. Finance, will participate in the following leading U.S. investor conferences:
Jefferies Annual NY Biotech Conference

Dates: June 2-4, 2026

Location: New-York

Presentation: 9:55 AM ET June 4, 2026

Live webcast and replay:
https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/Bz7fjGhGyU3meEzqRduiXr

Evercore Summer Symposium

Dates: June 22-24, 2026

Location: Newport, Rhode Island

To schedule a meeting, please contact the conference organizers or reach out directly to Medincell.
About Medincell
Medincell is a clinical- and commercial-stage biopharmaceutical

Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June

Tue, 26 May 2026 12:00:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced that Christophe Douat, Chief Executive Officer, and Grace Kim, Chief Strategy Officer, U.S. Finance, will participate in the following leading U.S. investor conferences:
Jefferies Annual NY Biotech Conference

Dates: June 2-4, 2026

Location: New-York

Presentation: 9:55 AM ET June 4, 2026

Live webcast and replay:
https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/Bz7fjGhGyU3meEzqRduiXr

Evercore Summer Symposium

Dates: June 22-24, 2026

Location: Newport, Rhode Island

To schedule a meeting, please contact the conference organizers or reach out directly to Medincell.
About Medincell
Medincell is a clinical- and commercial-stage biopharmaceutical

Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June

Tue, 26 May 2026 12:00:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced that Christophe Douat, Chief Executive Officer, and Grace Kim, Chief Strategy Officer, U.S. Finance, will participate in the following leading U.S. investor conferences:
Jefferies Annual NY Biotech Conference

Dates: June 2-4, 2026

Location: New-York

Presentation: 9:55 AM ET June 4, 2026

Live webcast and replay:
https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/Bz7fjGhGyU3meEzqRduiXr

Evercore Summer Symposium

Dates: June 22-24, 2026

Location: Newport, Rhode Island

To schedule a meeting, please contact the conference organizers or reach out directly to Medincell.
About Medincell
Medincell is a clinical- and commercial-stage biopharmaceutical

Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June

Tue, 26 May 2026 12:00:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced that Christophe Douat, Chief Executive Officer, and Grace Kim, Chief Strategy Officer, U.S. Finance, will participate in the following leading U.S. investor conferences:
Jefferies Annual NY Biotech Conference

Dates: June 2-4, 2026

Location: New-York

Presentation: 9:55 AM ET June 4, 2026

Live webcast and replay:
https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/Bz7fjGhGyU3meEzqRduiXr

Evercore Summer Symposium

Dates: June 22-24, 2026

Location: Newport, Rhode Island

To schedule a meeting, please contact the conference organizers or reach out directly to Medincell.
About Medincell
Medincell is a clinical- and commercial-stage biopharmaceutical

Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June

Tue, 26 May 2026 12:00:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced that Christophe Douat, Chief Executive Officer, and Grace Kim, Chief Strategy Officer, U.S. Finance, will participate in the following leading U.S. investor conferences:
Jefferies Annual NY Biotech Conference

Dates: June 2-4, 2026

Location: New-York

Presentation: 9:55 AM ET June 4, 2026

Live webcast and replay:
https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/Bz7fjGhGyU3meEzqRduiXr

Evercore Summer Symposium

Dates: June 22-24, 2026

Location: Newport, Rhode Island

To schedule a meeting, please contact the conference organizers or reach out directly to Medincell.
About Medincell
Medincell is a clinical- and commercial-stage biopharmaceutical

Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June

Tue, 26 May 2026 12:00:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced that Christophe Douat, Chief Executive Officer, and Grace Kim, Chief Strategy Officer, U.S. Finance, will participate in the following leading U.S. investor conferences:
Jefferies Annual NY Biotech Conference

Dates: June 2-4, 2026

Location: New-York

Presentation: 9:55 AM ET June 4, 2026

Live webcast and replay:
https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/Bz7fjGhGyU3meEzqRduiXr

Evercore Summer Symposium

Dates: June 22-24, 2026

Location: Newport, Rhode Island

To schedule a meeting, please contact the conference organizers or reach out directly to Medincell.
About Medincell
Medincell is a clinical- and commercial-stage biopharmaceutical

Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June

Tue, 26 May 2026 12:00:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced that Christophe Douat, Chief Executive Officer, and Grace Kim, Chief Strategy Officer, U.S. Finance, will participate in the following leading U.S. investor conferences:
Jefferies Annual NY Biotech Conference

Dates: June 2-4, 2026

Location: New-York

Presentation: 9:55 AM ET June 4, 2026

Live webcast and replay:
https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/Bz7fjGhGyU3meEzqRduiXr

Evercore Summer Symposium

Dates: June 22-24, 2026

Location: Newport, Rhode Island

To schedule a meeting, please contact the conference organizers or reach out directly to Medincell.
About Medincell
Medincell is a clinical- and commercial-stage biopharmaceutical

Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June

Tue, 26 May 2026 12:00:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced that Christophe Douat, Chief Executive Officer, and Grace Kim, Chief Strategy Officer, U.S. Finance, will participate in the following leading U.S. investor conferences:
Jefferies Annual NY Biotech Conference

Dates: June 2-4, 2026

Location: New-York

Presentation: 9:55 AM ET June 4, 2026

Live webcast and replay:
https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/Bz7fjGhGyU3meEzqRduiXr

Evercore Summer Symposium

Dates: June 22-24, 2026

Location: Newport, Rhode Island

To schedule a meeting, please contact the conference organizers or reach out directly to Medincell.
About Medincell
Medincell is a clinical- and commercial-stage biopharmaceutical

Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June

Tue, 26 May 2026 12:00:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced that Christophe Douat, Chief Executive Officer, and Grace Kim, Chief Strategy Officer, U.S. Finance, will participate in the following leading U.S. investor conferences:
Jefferies Annual NY Biotech Conference

Dates: June 2-4, 2026

Location: New-York

Presentation: 9:55 AM ET June 4, 2026

Live webcast and replay:
https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/Bz7fjGhGyU3meEzqRduiXr

Evercore Summer Symposium

Dates: June 22-24, 2026

Location: Newport, Rhode Island

To schedule a meeting, please contact the conference organizers or reach out directly to Medincell.
About Medincell
Medincell is a clinical- and commercial-stage biopharmaceutical

Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June

Tue, 26 May 2026 12:00:00 -0400

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced that Christophe Douat, Chief Executive Officer, and Grace Kim, Chief Strategy Officer, U.S. Finance, will participate in the following leading U.S. investor conferences:
Jefferies Annual NY Biotech Conference

Dates: June 2-4, 2026

Location: New-York

Presentation: 9:55 AM ET June 4, 2026

Live webcast and replay:
https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/Bz7fjGhGyU3meEzqRduiXr

Evercore Summer Symposium

Dates: June 22-24, 2026

Location: Newport, Rhode Island

To schedule a meeting, please contact the conference organizers or reach out directly to Medincell.
About Medincell
Medincell is a clinical- and commercial-stage biopharmaceutical

EMA accepts Teva application for long-acting olanzapine schizophrenia drug

Thu, 21 May 2026 13:24:16 -0400

The European Medicines Agency has accepted Teva Pharmaceutical Industries Ltd.'s (NYSE: TEVA) marketing authorization application for TEV-'749, a long-acting injectable formulation of olanzapine for treating schizophrenia in adults.

The subcutaneous injection is designed to be administered every four weeks and utilizes Medincell's (Euronext: MEDCL) SteadyTeq technology for controlled drug release. TEV-'749 has not received regulatory approval from any authority worldwide.

The application is supported by clinical development including the Phase 3 SOLARIS study. According to the companies, the treatment demonstrated efficacy and a safety profile consistent with oral olanzapine across clinical trials.

"Treatment adherence remains a challenge for people living with schizophrenia including